Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option Dupixent significantly reduced severe asthma ...
Read moreDetails
